Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Pharmacology Research & Perspectives|October 6, 2023
Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjectsBenjamin Berger, Priska Kaufmann, Matthias Berse, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|February 15, 2024
The metabolism of the orexin-1 selective receptor antagonist nivasorexantAlexander Treiber, Swen Seeland, Belal Haschimi, et al.
Clinical Pharmacology and Therapeutics|April 17, 2002
In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburidePaul L M van Giersbergen, Alexander Treiber, Martine Clozel, et al.
European Journal of Clinical Pharmacology|October 18, 2014
Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonistMartine Gehin, Patricia N Sidharta, Carmela Gnerre, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|February 23, 2018
Cross-species comparison of the metabolism and excretion of selexipagTomohiko Ichikawa, Tetsuhiro Yamada, Alexander Treiber, et al.
European Journal of Pharmacology|September 27, 2002
Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptorPaul L M van Giersbergen, Carmela Gnerre, Alexander Treiber, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 5, 2015
The metabolism of the dual endothelin receptor antagonist macitentan in rat and dogAlexander Treiber, Tommaso Miraval, Martin H Bolli, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 29, 2014
Macitentan does not interfere with hepatic bile salt transportAlexander Treiber, Päivi Äänismaa, Ruben de Kanter, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 31, 2012
Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humansShirin Bruderer, Gérard Hopfgartner, Michael Seiberling, et al.
Chemmedchem|April 17, 2013
Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonistMichel A Steiner, John Gatfield, Catherine Brisbare-Roch, et al.
Pageof 5